Echo Therapeutics disclosed in a regulatory filing, that on June 30, the Board of Directors of Echo Therapeutics appointed Kimberly A. Burke to serve as Interim CEO of Echo, effective July 1 and continuing for the sixty-day period expiring on August 30 or, if earlier, such date as a candidate is identified and appointed by the Board to serve as Echo’s CEO. Ms. Burke will also serve as Echo’s principal executive officer. The Board is currently working with a retained executive search firm to identify qualified candidates to serve as Echo’s CEO. In addition to serving as Interim CEO, Ms. Burke will also continue to serve as the General Counsel and Chief Compliance Officer of Echo. Effective at midnight on June 30, Robert F. Doman’s consulting contract with Echo expired in accordance with its terms and, accordingly, he no longer serves as the Interim CEO of Echo .On July 1, Christopher P. Schnittker resigned as SVP and CFO of Echo to accept another opportunity. Mr. Schnittker’s resignation is effective as of July 15. Echo has initiated a search for a new CFO.